[New hydroxylapatite cement for craniofacial surgery]

Current biomaterials for craniofacial reconstruction face limitations in terms of setting behavior, mechanical properties, and biocompatibility. Traditional hydroxylapatite cements often exhibit undesirable thermal changes or expansion during setting. While hydroxylapatite is known for its osteoconductive properties, its application in clinical settings has been constrained by factors like handling and stability. Prior research has shown that hydroxylapatite can integrate with bone but requires specific conditions for successful application. No prior work had resolved the issue of a stable, isothermic, and osteoconductive cement suitable for craniofacial use. This gap motivated the development of a new hydroxylapatite cement formulation. The need for a material that avoids thermal changes and maintains structural integrity during setting remains unmet. This paper's contribution lies in introducing a cement that addresses these challenges. The study focuses on a novel hydroxylapatite cement suitable for non-load-bearing craniofacial applications.

The aim of this study is to evaluate a new hydroxylapatite cement composed of a stoechiometric mixture of dicalcium-phosphate and tetra-calcium-phosphate. The objective is to assess its suitability for craniofacial surgery based on its setting properties and structural stability. The specific problem addressed is the lack of a stable, isothermic cement that avoids thermal changes during setting. The motivation stems from the clinical need for a material that supports bone reconstruction without causing complications. The researchers propose that this cement could improve outcomes in craniofacial reconstruction. The study focuses on the material's conversion to hydroxylapatite and its mechanical properties. The goal is to provide a new option for non-load-bearing applications in craniofacial surgery. The paper evaluates the material's performance in clinical settings.

The new cement is prepared intraoperatively by mixing 27% dicalcium-phosphate and 73% tetra-calcium-phosphate with water. The mixture is applied as a paste and sets to hydroxylapatite. The setting time is approximately 20 minutes, with pH ranging from 6.5 to 8.5. The material is tested for compressive and tensile strength. Mechanical properties are measured using standard methods. The cement is observed in a physiological environment for four hours to assess its conversion to hydroxylapatite. The study includes clinical applications in nine of ten patients. The researchers monitor the material's stability and handling characteristics. The approach combines in vitro testing with clinical evaluation.

The new cement sets within 20 minutes and achieves a compressive strength of about 50 MPa and a tensile strength of about 8 MPa. The pH during setting ranges from 6.5 to 8.5, avoiding thermal changes. The cement converts to hydroxylapatite within four hours in physiological conditions. It is no longer redissolvable in normal body fluids. The material is suitable for non-load-bearing applications in craniofacial surgery. Nine out of ten patients had successful reconstructions using this cement. The cement is used for cranial defects due to tumours or trauma. It is also suitable for filling dentoalveolar cysts and defects following dental apectomy.

The authors propose that the new hydroxylapatite cement is suitable for non-load-bearing applications in craniofacial surgery. The material's isothermic reaction and conversion to hydroxylapatite support its use in clinical settings. The cement's compressive and tensile strength values are suitable for craniofacial applications. The material's pH during setting avoids thermal changes, making it safe for use. The study suggests that the cement is stable and not redissolvable in normal body fluids. The authors suggest that the cement could be used for filling dentoalveolar cysts and defects. It is also suitable for reconstructing cranial defects due to tumours or trauma. The perspectives for the cement include its potential as a carrier for osteogenic protein preparations.